Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T15:13:10.006Z.
Calculation as of: 2026-10-06T15:13:10.006Z.
Quote observation: 2026-10-05T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$560.75M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$556.18M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$569.29M
Price/OCF Ratio
N/A
TTM Avg
41.16
3Y Avg
40.24
5Y Avg
16.59
Market Cap
$570.25M
Price/OCF Ratio
N/A
TTM Avg
14.09
3Y Avg
14.09
5Y Avg
14.09
Market Cap
$582.28M
Price/OCF Ratio
78.60
TTM Avg
75.01
3Y Avg
75.01
5Y Avg
75.01
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MiniMed Group, Inc. (MMEDV) | $560.00M | N/A | N/A | N/A | N/A |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $560.75M | N/A | N/A | N/A | N/A |
| CorMedix Inc. (CRMD)vs › | $563.68M | 2.22 | 8.23 | 11.13 | 11.13 |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $556.18M | N/A | N/A | N/A | N/A |
| CytomX Therapeutics, Inc. (CTMX)vs › | $569.29M | N/A | 41.16 | 40.24 | 16.59 |
| Aquestive Therapeutics, Inc. (AQST)vs › | $570.25M | N/A | 14.09 | 14.09 | 14.09 |
| Nuvectis Pharma, Inc. (NVCT)vs › | $549.04M | N/A | N/A | N/A | N/A |
| Immix Biopharma, Inc. (IMMX)vs › | $541.30M | N/A | N/A | N/A | N/A |
| OrthoPediatrics Corp. (KIDS)vs › | $582.28M | 78.60 | 75.01 | 75.01 | 75.01 |
| Delcath Systems, Inc. (DCTH)vs › | $537.34M | 27.43 | 30.64 | 39.07 | 39.07 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
